Nordtech (NTECH.ST) traded down -2.64 % during a 24 hours period ending at 10:07 PM Central Europe on Tuesday 27th. One Nordtech stock can currently be bought for about SEK 64.5 on popular exchanges. Current supply of Nordtech stocks is 51.8 mn. Nordtech has a current market capitalization of SEK 3.3 bn and approximately SEK 260.8 k worth of Nordtech was traded on exchanges in the last 24 hours. Since last month end, Nordtech has traded -6.52 % down. Simple moving average of last 200 days is at SEK 67.02. The highest price of past 52 weeks was recorded at SEK 79.7 on 08/04/2026. 52 weeks low was at SEK 55.4 on 07/17/2026.
Here is how related stocks have performed in the past 24 hours:
Byggmax (BMAX.ST) traded down -0.48 % and now trades at SEK 62.7. Current market capitalisation for Byggmax is SEK 3.7 bn. Byggmax has a current price to earnings ratio of 13.74.
Proact It (PACT.ST) traded up 3.18 % and now trades at SEK 151.4. Current market capitalisation for Proact It is SEK 3.9 bn. Current price/earnings ratio for Proact It is 16.74. Proact IT Group AB shares have recently reached new 52‑week highs on the Stockholm Exchange, trading above the previous peak in consecutive sessions. The stock’s price movement has attracted attention, prompting several institutional investors to adjust their holdings. Handelsbanken Fonder, for example, reduced its stake in the company to just under five percent of capital and voting rights, following a regulatory threshold. These developments reflect ongoing interest in the firm’s market performance and the broader dynamics of Swedish technology stocks.
Meko (MEKO.ST) traded up 0.29 % and now trades at SEK 69.7. Meko has a market capitalisation of SEK 3.8 bn. Current price/earnings ratio for Meko is 29.73.
Oatly (9ZX0.F) traded down -4.19 % and now trades at EUR 10.85. Oatly has a market capitalisation of EUR 329.4 mn. Oatly Group is set to release its financial results for the quarter ended 30 September 2026 on 28 October. Analysts anticipate the company will report a modest operating loss, an improvement from the larger loss recorded in the same period the previous year. Revenue is expected to have risen by roughly nine percent, reaching close to a quarter‑billion dollars, up from the prior year’s figure. For the full fiscal year, projections suggest a smaller annual loss per share compared to last year, while overall sales are forecast to exceed the previous year’s earnings by a notable margin. The company’s performance is being monitored closely by analysts who have adjusted their outlooks in light of these expected results.
Hansa Biopharma (HNSA.ST) traded down -0.38 % and now trades at SEK 36.4. Hansa Biopharma has a market capitalisation of SEK 3.7 bn. Hansa Biopharma AB, a Swedish life‑science company, has recently announced changes to its senior management team. The firm has appointed a new director of investor relations and corporate affairs, a role that will oversee communication with the capital market, medical opinion leaders, patient groups, and other key stakeholders. This appointment follows the company’s broader strategy to strengthen its market presence and support ongoing development initiatives. In addition, Hansa Biopharma has released early financial guidance for the forthcoming quarter, with analysts projecting a significant improvement in earnings per share compared to the previous year’s results. While specific figures are not disclosed, expectations point to a marked turnaround in profitability, reflecting the company’s focus on expanding its commercial footprint and capitalising on its scientific portfolio. The update underscores the firm’s commitment to transparent financial reporting and strategic growth.